Somapacitan (Sogroya)
Overview
Somapacitan is a long-acting growth hormone analogue engineered by attaching an albumin-binding moiety to recombinant human growth hormone. This modification extends the half-life to allow once-weekly subcutaneous administration, compared to daily injections required for standard somatropin.
Mechanism of Action
The peptide retains growth hormone receptor agonist activity with pharmacokinetic enhancement intended to improve treatment adherence.
Research Summary & Key Findings
The REAL 1 trial (Journal of Clinical Endocrinology and Metabolism, 2020) demonstrated non-inferiority to daily somatropin in adult growth hormone deficiency, leading to FDA approval in August 2020. The REAL 2 trial confirmed efficacy in treatment-naïve adults with similar outcomes. Somapacitan represents the first once-weekly growth hormone replacement therapy approved in the United States.
Clinical Status
Somapacitan (Sogroya) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.
Administration Routes
References
Primary literature
- PubMed — "Somapacitan"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov — "Somapacitan"
Registered interventional and observational studies, including status and phase.
- PubChem — "Somapacitan"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Hormone
CJC-1295
In Clinical TrialsA synthetic analog of growth hormone-releasing hormone (GHRH) with a Drug Affinity Complex (DAC) that binds to albumin, ...
View detailsIpamorelin
In Clinical TrialsA highly selective growth hormone secretagogue that acts on ghrelin/GHS receptors in the pituitary gland to stimulate GH...
View detailsSermorelin
FDA ApprovedA synthetic 29-amino acid analog of GHRH representing the shortest fully functional fragment of the native 44-amino acid...
View detailsTesamorelin (Egrifta)
FDA ApprovedA synthetic GHRH analog consisting of the 44-amino acid sequence of human GHRH with a trans-3-hexenoic acid modification...
View detailsStart Your Consultation
Get an AI-proposed Somapacitan (Sogroya) protocol reviewed by a physician in our network.
Start Your ConsultationFind a Pharmacy
Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Somapacitan (Sogroya).
Pharmacy DirectoryJoin the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.